Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B-Reference-Cited by-同舟云学术

Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

Published:2013-12-12 Issue:24 Volume:369 Page:2313-2323
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Powell Jerry S.,Pasi K. John,Ragni Margaret V.,Ozelo Margareth C.,Valentino Leonard A.,Mahlangu Johnny N.,Josephson Neil C.,Perry David,Manco-Johnson Marilyn J.,Apte Shashikant,Baker Ross I.,Chan Godfrey C.,Novitzky Nicolas,Wong Raymond S.,Krassova Snejana,Allen Geoffrey,Jiang Haiyan,Innes Alison,Li Shuanglian,Cristiano Lynda M.,Goyal Jaya,Sommer Jurg M.,Dumont Jennifer A.,Nugent Karen,Vigliani Gloria,Brennan Aoife,Luk Alvin,Pierce Glenn F.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305074

Cited by 308 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B;Blood Advances;2024-09-24

2. Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B;Scientific Reports;2024-09-04

3. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology;Journal of Thrombosis and Haemostasis;2024-09

4. Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment;Expert Opinion on Investigational Drugs;2024-08-11

5. Joint health and pain in the changing hemophilia treatment landscape;Expert Review of Hematology;2024-07-15